Stockwinners Market Radar for November 14, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:43 EST Roche gets FDA approval for VENTANA FOLR1 assay for ELAHERE treatment - The company states: "Roche announced the FDA approval of the VENTANA FOLR1 RxDx Assay, the first immunohistochemistry companion diagnostic test to aid in identifying epithelial ovarian cancer patients who are eligible for targeted treatment with ELAHERE. ELAHERE is a first-in-class antibody-drug conjugate therapy developed by ImmunoGen, Inc., approved under FDA's Accelerated Approval program for the treatment of FR-positive platinum-resistant ovarian cancer. The approval is based on the results of the SORAYA clinical study.4 In the study, approximately 35% of ovarian cancer patients expressed high levels of FRalpha and were considered FRalpha-positive by the VENTANA FOLR1 RxDx Assay. Of the FRalpha-positive patients, about 32 percent demonstrated a partial or complete response to ELAHERE therapy."

19:09 EST Opendoor Technologies director sells $8.9M in common stock - In a regulatory filing, Opendoor Technologies disclosed that its director Glenn Solomon sold 4.7M shares of common stock on November 9th in a total transaction size of $8.9M.

18:42 EST Third Point buys TJX, exits Cenovus Energy in Q3 - Third Point disclosed in an SEC filing its holdings as of September 30, 2022. The fund's nine new buys during the third quarter included, by size of position, Bath & Body Works (BBWI), TJX (TJX), Range Resources (RRC), Ferguson (FERG), and Take-Two (TTWO). Third Point exited nine holdings during the quarter, including by size of previous position Cenovus Energy (CVE), Crown Holdings (CCK), Archaea Energy (LFG), Membership Collective (MCG), and Social Leverage Acquisition Corp. I (SLAC). The fund increased its stake in five holdings, including by size of previous position Colgate-Palmolive (CL), Danaher (DHR), UnitedHealth (UNH), Disney (DIS), and T-Mobile (TMUS). Third Point reduced its stake in ten holdings, including by size of previous position EQT Corp. (EQT), Antero Resources (AR), Ovintiv (OVV), CSX (CSX), and DuPont (DD). The fund's top holdings as of September 30, in order of size, were Colgate-Palmolive, PG&E (PCG), Danaher, UnitedHealth, and Bath & Body Works.

17:57 EST Carpenter Technology to raise base prices on Specialty Alloy Portfolio by 7%-12% - Carpenter Technology "announced that it will increase base prices by an average of seven percent to twelve percent on new, non-contract orders across the majority of its premium products. The increases will be effective with new orders placed after November 15, 2022. All applicable surcharges will remain in effect."

17:52 EST User reports indicate problems at DoorDash, Downdetector says - Reference Link

17:44 EST Sun Life names Tom Murphy chief risk officer - Sun Life announced the appointment of Tom Murphy as Executive Vice-President and Chief Risk Officer, effective December 1, 2022. Tom is currently President of Fixed Income and Head of Institutional Business for SLC Management, Sun Life's alternatives asset manager. "We're excited to have Tom join Sun Life's Executive Team as our Chief Risk Officer. Tom's global depth of knowledge and experience, particularly in asset management and the pension space, will be a tremendous asset to his new role," said Kevin Strain, President and CEO of Sun Life. "Sun Life's approach to prudent risk management has always been a pillar of our success and having Tom leading and taking a fresh look at these efforts will serve our company well."

17:34 EST Denny's director sells $2.24M in common stock - In a regulatory filing, Denny's disclosed that its director John Miller sold 185K shares of common stock on November 9th in a total transaction size of $2.24M.

17:27 EST Google debuts Health Connect beta, supports Peloton, Oura, WeightWatchers apps - "We are now making the Health Connect (Beta) app available for download in Google Play (GOOG, GOOGL) to give users a central place to manage their privacy settings with granular controls to see which apps have access to data at any given time. "Today, 10+ health, fitness and wellness apps are rolling out integrations with the platform including early adopters of Health Connect like MyFitnessPal, Oura and Peloton (PTON)...In the past, developers had to establish multiple API connections to share data between different apps and each integration was costly to build and maintain. This limited developers' data sharing capabilities and made it hard for users to unlock this data so that it could be utilized in different apps. Now, with Health Connect, building an integration with a new app is as simple as reading in new data from Health Connect, rather than building a whole new integration. For example, Android users will now be able to sync and get credit for their Peloton workouts in apps like Oura, MyFitnessPal, WeightWatchers (WW) and Lifesum. Now, through a single integration with Health Connect, Peloton Members will have the option to share their workout stats across the ecosystem of apps they use to support their overall wellness," wrote Sara Hamilton, Developer Relations, in part, on the on the Android Developers Blog for Google. Reference Link

17:26 EST Starboard takes stake in Wix.com, exits Elanco Animal Health - Jeffrey Smith's Starboard Value disclosed in an SEC filing its holdings as of September 30, 2022. Starboard's five new buys during the quarter included, by size of position, Wix.com (WIX), Selina Hospitality (SLNA), Monterey Capital Acquisition Corp (MCAC), and Acri Capital Acquisition Corp (ACAC). Starboard exited eleven positions during the quarter, including by size of previous position, Elanco Animal Health (ELAN), Corteva (CTVA), Merit Medical Systems (MMSI), Kohl's (KSS), and GigCapital5 (GIA). Starboard increased its stake in three holdings, including by size of previous position, Atlantic Coastal Acquisition (ACAH) and Legato Merger Corp II (LGTO). Starboard reduced its stake in ten holdings, including by size of previous position, ON Semiconductor (ON), Huntsman (HUN), ACI Worldwide (ACIW), Mercury Systems (MRCY), and CommVault Systems (CVLT). Starboard's top holdings as of September 30, in order of size, were GoDaddy (GDDY), Aecom (ACM), Humana (HUM), Willis Towers Watson (WTW), and Gen Digital (GEN).

17:20 EST Conformis enters settlement, license agreement with Medacta USA - Conformis announced that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta International SA that resolves all patent disputes between the companies. Under the terms of the settlement, Medacta will receive a non-exclusive license to certain Conformis patents related to patient-specific instrumentation for use with off-the-shelf knee and shoulder implants.

17:17 EST Paulson adds Rumble, exits Occidental in Q3 - John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of September 30, 2022. The fund's three new buys during the third quarter included Rumble (RMBL). Paulson exited seven holdings during the quarter, including by size of previous position Occidental (OXY), Pacira BioSciences (PCRX), and Endo (ENDP). The fund decreased its stake in nine holdings, including by size of previous position Horizon Therapeutics (HZNP), APA Corp. (APA), Barrick Gold (GOLD), KraneShares CSI China Internet ETF (KWEB), and AngloGold Ashanti (AU). Paulson's top holdings as of September 30, in order of size, were Horizon Therapeutics (HZNP), Bausch Health (BHC), Brightsphere Investment (BSIG), Novagold Resources (NG), and KraneShares CSI China Internet ETF.

17:09 EST Magnite, Horizon Media announce multi-year deal - Magnite announced a multi-year deal with Horizon Media. The deal is an expansion of Magnite and Horizon Media's existing relationship, focusing on supply path optimization and encompasses Horizon Media's buys across all formats including CTV, online video, display, mobile and audio.

17:04 EST S&P Global reaches settlement with SEC - S&P Global Ratings, a division of S&P Global, announced that it has reached a settlement with the U.S. Securities and Exchange Commission to resolve an SEC investigation involving the ratings assigned to a single residential mortgage-backed securities transaction in 2017. The matter was previously disclosed by S&P Global in its public filings. As part of the resolution, in which SPGR did not admit or deny the allegations, the company agreed to pay a penalty of $2.5M. In the SEC's order, the SEC acknowledged SPGR's remedial acts and its cooperation with the SEC staff. SPGR is pleased to have concluded this matter. SPGR takes compliance with regulatory obligations very seriously and is committed to the integrity of its ratings process and high-quality independent credit ratings.

16:59 EST Wintrust to acquire two businesses from Rothschild & Co North America - Wintrust Financial and Rothschild & Co announced they have entered into an agreement for Wintrust to acquire two asset management businesses from Rothschild & Co North America. Wintrust's subsidiary, Great Lakes Advisors, agreed to purchase Rothschild & Co Asset Management US Inc. and Rothschild & Co Risk Based Investments, investment managers with approximately $8B in assets under management specializing in equity investment strategies for institutional, intermediary and other clients. Upon completion of the transaction, Rothschild & Co Asset Management U.S. will merge into and operate the business as Great Lakes Advisors. The terms of the transaction are not being disclosed. The transaction is expected to be completed early in the first quarter of 2023, subject to certain closing conditions.

16:57 EST NYSE announces plans to suspend trading and delist Cohn Robbins - On November 10 the New York Stock Exchange issued a press release announcing that the staff of NYSE Regulation determined to suspend trading immediately and commence proceedings to delist the Class A ordinary shares, warrants and units of Cohn Robbins Holdings because the Company is not in compliance with the NYSE's continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. On November 10 the NYSE notified the Company in writing of the determination to suspend trading and commence proceedings. The Company has the right to a review of NYSE Regulation's determination by a Committee of the Board of Directors of the NYSE, and the NYSE will apply to the SEC to delist the Company Securities upon completion of all application procedures, including any appeal by the Company of NYSE Regulation's determination. The Company will consider all of its options, including its option to pursue a review, in responding to the NYSE notification.

16:56 EST Azenta jumps 33% to $62.07 after Q4 earnings beat and guidance

16:54 EST Nelson Peltz's Trian boosts P&G, cuts Ferguson in Q3 - Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of September 30, 2022. The fund increased its stake in two holdings during the third quarter, including by size of previous position Procter & Gamble (PG) and General Electric (GE). Trian decreased its stake in two holdings, including by size of previous position Ferguson (FERG) and Sysco (SYY). The fund's top holdings as of September 30, in order of size, were Ferguson, Invesco (IVZ), Janus Henderson (JHG), Sysco, and Wendy's (WEN).

16:50 EST Pershing Square take new stake in Intel, exits position in Atlas Air - Bill Ackman's Pershing Square Capital Management disclosed in an SEC filing its holdings as of September 30, 2022. Pershing Square's two new buys during the quarter included, by size of position, Intel (INTC). Pershing Square exited seven positions during the quarter, including by size of previous position, Atlas Air (AAWW), Chemours (CC), International Seaways (INSW), Plby Group (PLBY), and AST SpaceMobile (ASTS). Pershing Square increased its stake in nine holdings, including by size of previous position, Consol Energy (CEIX), LivaNova (LIVN), Southwestern Energy (SWN), KynDryl Holdings (KD), and Concentrix (CNXC). Pershing Square reduced its stake in six holdings, including by size of previous position, Global Payments (GPN), Victoria's Secret (VSCO), Brighthouse Financial (BHF), and Green Brick Partners (GRBK). Pershing Square's top holdings as of September 30, in order of size, were Green Brick, Brighthouse, Consol Energy, Teck Resources (TECK), and Kyndryl Holdings.

16:40 EST Elliott made Triple Flag Precious Metals top holding during Q3 - Paul Singer's Elliott Management disclosed in an SEC filing its holdings as of September 30, 2022. The fund made five new during Q3: Triple Flag Precious Metals (TFPM), iShares iBoxx $ Investment Grade Corporate Bond (LQD), Cardinal Health (CAH), Clarivate (CLVT) and Bausch Health (BHC). Elliott exited three positions during the quarter, including Diamond Offshore (DO) and Principal Financial (PFG). The fund increased its stake in three holdings: Pinterest (PINS), Valaris (VAL) and E2open (ETWO). It decreased its stake in two holdings: Howmet Aerospace (HWM) and Uniti Group (UNIT). Elliott's top holdings as of September 30, in order of size, were Triple Flag Precious Metals, Howmet, Marathon Petroleum (MPC), Peabody Energy (BTU) and Pinterest.

16:34 EST ImmunoGen announces FDA accelerated approval of ELAHERE - ImmunoGen announced that the US Food and Drug Administration has granted accelerated approval for ELAHERE for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ELAHERE was approved under FDA's accelerated approval program based on objective response rate and duration of response data from the pivotal SORAYA trial. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. ELAHERE is a first-in-class ADC directed against FRalpha, a cell-surface protein highly expressed in ovarian cancer, and is the first FDA approved ADC for platinum-resistant disease. "The approval of ELAHERE is significant for patients with FRalpha-positive platinum-resistant ovarian cancer, which is characterized by limited treatment options and poor outcomes," said Ursula Matulonis, MD, Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at the Harvard Medical School, and SORAYA Co-Principal Investigator. "ELAHERE's impressive anti-tumor activity, durability of response, and overall tolerability observed in SORAYA demonstrate the benefit of this new therapeutic option, and I look forward to treating patients with ELAHERE."

16:32 EST Insulet issues nationwide voluntary device correction for Omnipod 5 controller - Insulet "announced a Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable. This does not impact the Omnipod 5 Pod, the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, or compatible Android smartphone devices that have the Omnipod 5 App installed. These actions are taken voluntarily with the knowledge of the FDA. Insulet has received 24 reports that the Omnipod 5 Controller charging port or cable are melting, deforming, or discoloring due to heat generated by a poor connection between the cable and the port. The excess heat may cause minor burns if those areas of the Controller are touched or could lead to fire. No serious injuries have been reported to Insulet as a result of this issue. "

16:31 EST Installed Building Products acquires Surface Purveyors - Installed Building Products "announced the acquisition of Surface Purveyors, LLC doing business as Lynch Insulation. Established in 1979, Lynch has locations in Missoula, MT and Hamilton, MT. Lynch primarily installs fiberglass and spray foam insulation into multifamily, residential, and commercial projects in Montana." With approximately $5 million of annual revenue, Lynch expands our presence in Montana," stated Jeff Edwards, CEO.

16:30 EST Lone Pine adds Autodesk stake, reduces Meta Platforms, Microsoft stakes - Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of September 30, 2022. Lone Pine's seven new buys during the quarter included, by size of position, Autodesk (ADSK), TransDigm (TDG), PTC (PTC), and Cheniere Energy (LNG). Lone Pine exited six positions during the quarter, including by size of previous position, ServiceNow (NOW), Alphabet (GOOGL), Atlassian (TEAM), Fair Isaac (FICO), and Vtex (VTEX). Lone Pine increased its stake in four holdings, including by size of previous position, PayPal (PYPL), UnitedHealth (UNH), and Booking Holdings (BKNG). Lone Pine reduced its stake in ten holdings, including by size of previous position, Meta Platforms (META), Microsoft (MSFT), Amazon (AMZN), Thermo Fisher Scientific (TMO), and First Citizens BancShares (FCNCA). Lone Pine's top holdings as of September 30, in order of size, were Workday (WDAY), Amazon, PayPal, Bath & Body Works (BBWI), and Microsoft.

16:30 EST Neoleukin Therapeutics trading resumes

16:27 EST Berkshire Hathaway adds TSMC, exits STORE Capital in Q3 - Warren Buffett's Berkshire Hathaway (BRK.A) disclosed in an SEC filing its holdings as of September 30, 2022. Berkshire's three new buys during the third quarter included, by size of position, TSMC (TSM), Louisiana-Pacific (LPX), and Jefferies Financial (JEF). The fund exited one holding during the quarter, namely STORE Capital (STOR). Berkshire increased its stake in five holdings, including by size of previous position Occidental (OXY), Chevron (CVX), RH (RH), Paramount Global Class B (PARA), and Celanese (CE). The fund decreased its stake in five holdings, including by size of previous position U.S. Bancorp (USB), Activision Blizzard (ATVI), BNY Mellon (BK), Kroger (KR), and General Motors (GM). The fund's top holdings as of September 30, in order of size, were Apple (AAPL), Bank of America (BAC), Chevron, Coca-Cola (KO), and American Express (AXP).

16:21 EST Gatos Silver names Ernst & Young as Auditor - Gatos Silver "announced the appointment of Ernst & Young LLP as independent registered public accounting firm of the Company, effective immediately. Gatos Silver selected EY based on their reputation and scale of international capabilities. EY is a well-respected top tier global accounting firm with a strong mining practice. The appointment of EY was approved by the Company's Board and Audit Committee."

16:19 EST Lippert acquires Way Interglobal, terms not disclosed - LCI Industries, through its wholly-owned subsidiary, Lippert Components, which supplies a broad array of highly engineered components for the leading original equipment manufacturers in the recreation and transportation product markets, and the related aftermarkets of those industries, announced that its subsidiary, Furrion LLC, has acquired substantially all of the business assets of Way Interglobal Network LLC. Way, headquartered in Elkhart, Indiana, designs, develops, and supplies innovative appliances and electronics to the RV Industry. The acquisition does not include Way's current power generator assets and operations. "With the addition of Way Interglobal and its associated brands to our core lineup of products, Lippert has now become one of the largest and most innovative appliance suppliers in the RV Industry," said Ryan Smith, Group President of Lippert's North American OEM businesses. Continued Smith, "Lippert will continue to push forward with innovation in this space with our combined resources, developing the products and solutions that our industry needs as we closely follow the ongoing trends of our markets."

16:17 EST AGBA Acquisition completes business combination with TAG Holdings - AGBA Acquisition Limited announced that it has completed its business combination with TAG Holdings Limited pursuant to the Business Combination Agreement, dated November 3, 2021, between it, TAG, and the other parties to the agreement. Through an acquisition merger, AGBA has become the 100% owner of the issued and outstanding securities of each of TAG International Limited and TAG Asia Capital Holdings Limited, each formerly wholly-owned subsidiaries of TAG. The business combination was approved by AGBA's shareholders at an extraordinary general meeting on November 10, 2022. The post-combination company has been renamed, "AGBA Group Holding Limited" and its ordinary shares and warrants are expected to begin trading on the Nasdaq Capital Market on November 15, 2022 under the ticker symbol "AGBA." Under its new name, AGBA will operate the TAG Business and its OnePlatform brand, which offers a full-service platform to banks, other financial institutions, brokers, and individual independent financial advisors to advise and serve its retail clients.

16:16 EST Horizon Technology Finance announces completion of $158M securitization - Horizon Technology Finance Corporation announced that Horizon Funding Trust 2022-1, a newly-formed wholly-owned subsidiary of Horizon, has issued $100 million of Notes rated A by a rating agency and which is backed by $158 million of secured loans originated by Horizon. KeyBanc Capital Markets served as sole Placement Agent and Initial Purchaser of the Notes, and Horizon is the Sponsor, Seller and Servicer for the transaction. The Notes bear interest at a fixed interest rate of 7.56% per annum and have a stated maturity date of November 15, 2030. "We are pleased to successfully complete this transaction, which increases our overall capacity to originate new venture debt loans and positions us to further grow our portfolio," said Daniel R. Trolio, Executive Senior Vice President and Chief Financial Officer of Horizon. "With this new financing, we believe we are now in an even better position to deliver long-term value to our shareholders."

16:15 EST Enviva names Thomas Meth CEO - Enviva announced that Thomas Meth, Enviva's President, has been appointed the Company's Chief Executive Officer and will become a member of Enviva's board of directors, while retaining his title as President. The Company also announced that John Keppler, Chairman and Chief Executive Officer, is expected to assume the role of Executive Chairman, consistent with the succession plan developed by the Board. Prior to doing so, Mr. Keppler will be stepping down from his responsibilities to pursue medical and surgical treatment to address a cardiac valve issue. The Company expects Mr. Keppler, who co-founded Enviva in 2004 with Mr. Meth, to remain available to the Company, and to return in the active Executive Chairman role early in 2023. Additionally, the Company announced that Ralph Alexander, who has been a member of the Board since 2013, will fulfill Mr. Keppler's duties as Chairman of the Board until Mr. Keppler's return, when Mr. Alexander is expected to become Lead Independent Director.

16:14 EST Universal Insurance announces 13c special dividend - Universal Insurance "announced that its Board of Directors has declared a regular quarterly cash dividend and a special cash dividend, together totaling 29 cents per share of common stock, payable December 16, 2022 to shareholders of record as of the close of business on December 9, 2022. The 29 cent per share dividend consists of a regular quarterly cash dividend of 16 cents per share and a special cash dividend of 13 cents per share, bringing the total regular and special dividends declared in 2022 to 77 cents per share."

16:11 EST Trevi Therapeutics names David Clark as chief medical officer - Trevi Therapeutics announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs. Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals.

16:09 EST Holley names Brian Appelgate as interim COO - Holley "announced the appointment of Brian Appelgate, an industry veteran and operating leader with decades of experience leading teams in the performance automotive aftermarket, to Interim Chief Operating Officer (COO). Mr. Appelgate, who has advised Holley since 2018 as Head of Mergers and Acquisitions, will further align Holley's operations in support of the Company's highest priorities and largest near-term opportunities."

16:05 EST NovaBay announces 1-for-35 reverse stock split - NovaBay Pharmaceuticals announced that, following approval from the company's stockholders obtained at the company's November 10, 2022 special stockholders' meeting, the company's Board of Directors has approved the filing of an amendment to the company's Amended and Restated Certificate of Incorporation, as amended, to effect a 1-for-35 reverse stock split of all outstanding shares of common stock of the company. The company anticipates that the 1-for-35 reverse stock split will be effective as of 4:15 p.m. New York City Time on Tuesday, November 15, 2022, and the company's common stock will begin trading on a split-adjusted basis on Wednesday, November 16, 2022.

16:01 EST Neoleukin Therapeutics trading halted, news pending

15:52 EST NYSE to suspend trading immediately in securities of Industrial Human Capital - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the securities of Industrial Human Capital from the Exchange. Trading in the company's Securities will be suspended immediately. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the securities upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision.

15:18 EST General Mills director Cordani sells 26,100 common shares - In a regulatory filing, General Mills director David Cordani disclosed the sale of 26,100 common shares of the company on November 11 at a price of $76.1848 per share.

14:33 EST DoorDash adds five new safety features for delivery workers - DoorDash shared an update on how it is adding new safety features for delivery workers. The five new features include SafeDash Check-In, which automatically checks in with the Dasher if a delivery is taking longer than expected; Real-Time Safety Alerts; SafeChat, which detects inappropriate or offensive language in a chat on its app and issues a warning to those who send such messages; Safety Reporting; and Porch Lights Reminders, which send notifications to customers asking them to turn their porch or house lights on as a Dasher is approaching. "When we launched SafeDash a year ago, it was a giant step forward in becoming the platform most trusted by individuals looking for app-based work," said Rajat Shroff, Vice President of Product at DoorDash. "As we continue to dream big in developing the best earnings platform for supplemental income, we're excited to roll out our largest safety product update ever, giving Dashers greater peace of mind while on the road." Reference Link

14:18 EST IAA holder Ancora says sales to Ritchie Bros. 'seemingly flawed' - Ancora Holdings, which is the beneficial owner of approximately 4% of the outstanding shares of IAA (IAA), sent the company's board a letter regarding the proposed sale to Ritchie Bros. Auctioneers (RBA) which reads in part: "We have had long-standing concerns regarding IAA's capital allocation, governance, operations and performance. That is why we previously called on the Board to either replace Chief Executive Officer John Kett or proceed with a formal sale process to maximize value for shareholders. Unfortunately, the Board appears to have ignored both requests prior to entering into a seemingly flawed and rushed transaction agreement with Ritchie Bros. last week. We view IAA's proposed sale to Ritchie Bros. as a poorly structured sweetheart deal that puts leadership's interests ahead of shareholders' best interests...If the current structure and terms remain intact, we intend to do everything in our power to oppose the transaction. This will be the case despite our belief that Ritchie Bros. is a very logical and synergistic combination partner for IAA under the right circumstances."

14:10 EST Insignia Systems trading resumes

13:55 EST Moderna says bivalent booster shows superiority against omicron variants - Earlier, Moderna announced that both of Moderna's bivalent Omicron-targeting booster candidates - mRNA-1273.214 and mRNA-1273.222 - trigger a superior antibody response compared to a booster dose of mRNA-1273, the company's prototype vaccine, against Omicron BA.4/BA.5 in Phase 2/3 clinical trials. Both bivalent vaccines also met non-inferiority immunogenicity criteria to the original strain. "We are pleased to see that both of our bivalent booster vaccine candidates offer superior protection against Omicron BA.4/BA.5 variants compared to our original booster, which is encouraging given COVID-19 remains a leading cause of hospitalization and death globally. In addition, the superior response against Omicron persisted for at least three months after the mRNA-1273.214 booster," said Stephane Bancel, Moderna's CEO. "Our bivalent boosters also show, in research assays, neutralizing activity against BQ.1.1, an increasingly dominant emerging variant, confirming that updated vaccines have the potential to offer protection as the virus continues to evolve rapidly to escape our immunity." In a Phase 2/3 study, a 50 B5g booster dose of mRNA-1273.222 elicited a superior neutralizing antibody response against Omicron BA.4/BA.5 variants when compared to a 50 B5g booster dose of mRNA-1273 in 511 previously vaccinated and boosted participants ages 19-89 years. Participants received mRNA-1273.222 and mRNA-1273 approximately 9.5 months and 4.5 months after their prior vaccination, respectively. Pre-booster BA.4/BA.5 titers were similar between the mRNA-1273.222 and mRNA-1273 groups. The Omicron BA.4/BA.5 geometric mean titer ratios of mRNA-1273.222 versus mRNA-1273 were 5.11 and 6.29 for participants with and without SARS-CoV-2 infection pre-booster, respectively. In all participants the GMT against Omicron BA.4/BA.5 was 4289, representing a 15.1-fold increase from pre-booster levels. For participants without prior infection, the GMT was 2325, representing a 26.4-fold increase and for those with prior infection, the GMT was 6965, representing a 9.8-fold increase from pre-booster levels. "Importantly, results were consistent between participants aged 65 years and older and those aged 18 to 65. In an exploratory analysis of approximately 40 participants using research assays, both bivalent vaccines demonstrated robust neutralizing activity against BQ.1.1, despite an approximately 5-fold drop in titers compared to BA.4/BA.5," the company stated.

13:02 EST Xerox appoints John Bruno as President and COO - Xerox announced the appointment of John Bruno as President and Chief Operating Officer. Bruno joins the team following Steven Bandrowczak's promotion to CEO earlier this year. Bruno comes to Xerox after seven years with Aon, where he most recently served as Chief Operating Officer and Chief Executive Officer of Data & Analytic Services. "In this role, John will partner closely with the CEO and leadership team to shape the company's global strategy and will be accountable for operating model advancements to improve company performance. He will also oversee global offerings, service delivery, marketing, manufacturing, supply chain, procurement, information technology, and Xerox's IT services business unit," the company said. "John brings decades of business, technology, and operations leadership experience at Fortune 500 companies across a wide range of industries that are applicable to the direction we're taking Xerox. John's expertise will help advance our client-centric operating model and enable us to create an even better overall customer experience," added Bandrowczak.

12:59 EST Inspirato Q3 earnings release delayed, pending restatements - In a regulatory filing earlier, Inspirato reported that the company will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 with the Securities and Exchange Commission within the prescribed time period due to delays in completion of the financial statements for the quarter. The filing stated: "In connection with the restatements discussed above, the company's management has re-evaluated the effectiveness of the company's disclosure controls and procedures as of March 31, 2022 and June 30, 2022 and based on that evaluation, the company's management has concluded its disclosure controls and procedures remained ineffective due to the unremediated material weaknesses previously disclosed in Item 4 'Controls and Procedures' in the company's Quarterly Reports on Form 10-Q filed with the SEC for the Non-Reliance Periods. Management is developing a remediation plan for the material weaknesses."

12:35 EST Jane Partners bought $5.42M worth of Momentive during Q3

12:00 EST Alight falls -13.7% - Alight is down -13.7%, or -$1.34 to $8.51.

12:00 EST Carvana falls -15.7% - Carvana is down -15.7%, or -$1.86 to $10.02.

12:00 EST HireRight rises 23.2% - HireRight is up 23.2%, or $1.79 to $9.49.

11:54 EST U.S. game content spending grew 2% y/y in October, says NPD - NPD analyst Mat Piscatella said that October U.S. video game content sales grew 2% vs last year, to $3.7B. Double-digit percentage growth in Console & PC content spending was driven by the launch of Activision's (ATVI) "Call of Duty: Modern Warfare II" in the October tracking period, compared to the launch of "Call of Duty: Vanguard" in November 2021. Eight of the top 20 best-selling premium games of October 2022 were new releases, including Warner Bros. Discovery's (WBD) "Gotham Knights," which ranked 2nd in October while debuting as the 14th best-selling game of 2022 year-to-date. Other top game sellers in October in the U.S. were Electronic Arts' (EA) "FIFA 23," "Madden NFL 23," and "NHL 23," Ubisoft's (UBSFY) "Mario + Rabbids: Sparks of Hope," Sega's (SGAMY) "Persona 5," Take-Two's (TTWO) "NBA 2K23," Nintendo's (NTDOY) "Bayonetta 3," and Bandai Namco's (NCBDY) "Elden Ring." Reference Link

11:50 EST U.S. video game spending totaled $4.3B in October, says NPD - NPD analyst Mat Piscatella said that U.S. consumer spending on video game content, hardware and accessories totaled $4.3B during the month of October 2022, flat when compared to a year ago. Octover growth in digital sales and subscriptions for console and PC video game content, driven in large part by the release of Activision's (ATVI) "Call of Duty: Modern Warfare II," was offset by declines in mobile content and hardware. Year-to-date spending has fallen 7% compared to this point in 2021, at $42.7B. Dollar sales of video game hardware fell 10% in October when compared to a year ago, to $424M. Double-digit percentage dollar sales growth for both PlayStation 5 (SONY) and Xbox Series (MSFT) consoles was offset by declines on other platforms. PlayStation 5 was the best-selling video game hardware of October in both unit and dollar sales, while Xbox Series ranked 2nd across both measures. Other companies in the video game space include Nintendo (NTDOY), Electronic Arts (EA), Take-Two (TTWO), Tencent (TCEHY), and Ubisoft (UBSFY). Reference Link

11:02 EST Microsoft announces 'Microsoft Supply Chain Platform' - Microsoft announced the "Microsoft Supply Chain Platform," which it said "helps organizations maximize their supply chain data estate investment with an open approach, bringing the best of Microsoft AI, collaboration, low-code, security and SaaS applications in a composable platform." The company also announced the preview of Microsoft Supply Chain Center, which it calls "a ready-made command center for supply chain visibility and transformation and part of the Microsoft Supply Chain Platform." Charles Lamanna, corporate vice president, Microsoft Business Applications and Platform, said: "Businesses are dealing with petabytes of data spread across legacy systems, ERP, supply chain management and point solutions, resulting in a fragmented view of the supply chain. Supply chain agility and resilience are directly tied to how well organizations connect and orchestrate their data across all relevant systems. The Microsoft Supply Chain Platform and Supply Chain Center enable organizations to make the most of their existing investments to gain insights and act quickly."

10:03 EST Foot Locker, PUMA expand partnership to reach next-generation customers - PUMA and Foot Locker announced an expanded partnership, underscored by a focus on basketball and the creation of exclusive product collections that meet the demands of this growing market segment. The companies also plan to roll out hyper-relevant creator engagements and brand partnerships that specifically resonate with a younger audience. Through this strengthened partnership, PUMA and Foot Locker have planned a series of exclusive collections and product collaborations with highly influential ambassadors reaching Gen Z and Gen Alpha. Specifics include: expanding the basketball and classics categories with continued exclusive access to the LaMelo Ball Signature program; launching the first-ever PUMA x POKEMON collaboration. PUMA and Foot Locker Inc. are partnering with The Pokemon Company International and Niantic, publisher of the popular Pokemon GO mobile game, to turn, for the next six months, 400 Foot Locker, Champs Sports, and Kids Foot Locker stores across the U.S. and the PUMA NYC Flagship store into Gyms and Poke Stops in Pokemon GO. PUMA x PAW PATROL, a new collection for kids will be available at exclusively at Kids Foot Locker and Foot Locker in North America starting November 25. creating and launching upcoming athlete capsules with Mikey Williams; building exclusive product programs to be released in the coming months with social media star and music artist Dixie D'Amelio and hip-hop artist Cordae; and launching PUMA x CoComelon, a new collaboration coming out next Spring and inspired by CoComelon's favorite characters, which will create a close connection with the younger generation available exclusively at Kids Foot Locker.

10:00 EST Altus Power falls -12.4% - Altus Power is down -12.4%, or -$1.06 to $7.48.

10:00 EST Circor rises 12.0% - Circor is up 12.0%, or $2.61 to $24.29.

10:00 EST HireRight rises 20.5% - HireRight is up 20.5%, or $1.58 to $9.29.

09:53 EST Knightscope receives contract for 41 machines from university in New Jersey - Knightscope announces a new contract at a New Jersey university for 31 of its K1 Blue Light Towers and 10 of its K1 Blue Light E-Phones.

09:47 EST Doximity falls -9.0% - Doximity is down -9.0%, or -$3.16 to $31.78.

09:47 EST ProShares UltraShort Bloomberg Natural Gas falls -12.6% - ProShares UltraShort Bloomberg Natural Gas is down -12.6%, or -$2.24 to $15.53.

09:47 EST KE Holdings rises 11.2% - KE Holdings is up 11.2%, or $1.52 to $15.05.

09:47 EST HireRight rises 13.2% - HireRight is up 13.2%, or $1.02 to $8.73.

09:43 EST Koch Industries bought 80.5M shares of Getty Images in Q3 - Koch Industries, in its quarterly filing of holdings as of September 30, disclosed a new stake in Getty Images of 80.5M shares. The stake is valued at $546.6M and represents 20% of Getty's outstanding shares.

09:42 EST AMC Entertainment trading resumes

09:37 EST POINT Biopharma Global Inc trading halted, volatility trading pause

09:37 EST AMC Entertainment trading halted, volatility trading pause

09:30 EST Apple CEO tells CBS that company has slowed down some hiring - In an interview with "CBS Mornings" co-host Nate Burleson, Apple CEO Tim Cook said that the company has slowed down some hiring. "We're being very deliberate in our hiring," Cook said, adding that the company is hiring "but not everywhere in the company." Reference Link

09:27 EST First Light Acquisition to transfer listing to the NYSE American on November 17 - First Light Acquisition recently announced a correction to the expected transfer date on its previously released press release. The company announced that it will transfer its listing to the NYSE American, where it has been approved to list. In connection with the transfer, FLAG will voluntarily delist from The New York Stock Exchange. FLAG's decision to transfer to the NYSE American was motivated by more favorable thresholds for continued listing on the NYSE American following recent redemptions of FLAG's Class A common stock. Following the transfer, FLAG intends to continue to file the same types of periodic reports and other information it currently files with the Securities and Exchange Commission. FLAG anticipates the transfer to the NYSE American to occur on or about November 17, 2022.

09:18 EST Diana Shipping announces delivery of Ultramax dry bulk vessel m/v DIS Andromeda - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the m/v DSI Andromeda, a 2016 built Ultramax dry bulk vessel of 60,309 dwt. The vessel is one of nine modern Ultramax dry bulk vessels that the Company entered into an agreement to purchase in August 2022. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ASL Bulk Marine Limited, for one of its Ultramax dry bulk vessels, the m/v DSI Polaris. The gross charter rate is US$13,100 per day, minus a 5% commission paid to third parties, for a period of minimum eighteen months to maximum twenty months. The charter commenced on November 12, 2022. The "DSI Polaris" is a 60,404 dwt Ultramax dry bulk vessel built in 2018. The employment of "DSI Polaris" is anticipated to generate approximately US$7.07 million of gross revenue for the minimum scheduled period of the time charter.

09:11 EST Lifecore completes corporate name change - Lifecore Biomedical has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical. In connection with this change, the company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" November 15. Lifecore's name change was accompanied by the previous transition of certain leadership positions, which included James Hall, who will continue to serve as Lifecore's President and CEO and as a director on the Board of Directors, as well as John Morberg, who will continue in his role of CFO of Lifecore. The composition of the Board was realigned to increase its focus on life sciences expertise. No action is required by stockholders with respect to the name or ticker symbol change and the changes will not affect the existing rights of stockholders.

09:11 EST Kruger Products to shut down older production assets in Memphis - KP Tissue and Kruger Products announced that it will shut down certain older and inefficient production assets including a Light Dry Crepe paper machine and six converting lines in early January, 2023 in Memphis, Tennessee. High quality facial tissue and premium Through Air Dry products will continue to be produced at its Memphis plant by approximately 400 remaining employees. The 165 employees impacted by this decision will receive severance and employment transition support. The Memphis plant is operated by Kruger Products' subsidiary, K.T.G. Inc. and after the asset shutdown will have a production capacity of 85,000 Metric Tonnes. "While this is a difficult decision, it is necessary to ensure the continued success, competitiveness, and growth of our Memphis plant. We have invested over $400 million at our Memphis plant since 2010 and it will continue to be an important part of our business. We would like to sincerely thank our employees for their ongoing dedication and hard work." said Dino Bianco, CEO of Kruger Products.

09:10 EST Sinclair Broadcast enters MOU with Hyundai Mobis to develop ATSC 3.0 services - Sinclair Broadcast announced that the company has entered into an MOU with Hyundai Mobis to collaborate on the development and implementation of ATSC 3.0-enabled automotive business models in both Korea and the United States. The collaboration expands Sinclair's coordination with the Korean market and the commitment to bring mobile services to the United States. Joint efforts on the development of new services, business opportunities and deployment models will include geo-targeting capabilities, enhanced GPS, software updates, in-vehicle entertainment, real-time emergency information and a myriad of other public services. The one-to-many architecture of ATSC 3.0 has the capability to provide highly efficient data and entertainment services to the roughly 20 million Hyundai, Kia, and Genesis vehicles in the United States.

09:10 EST Amerant Bancorp selected official bank of Florida Panthers - Amerant Bank and the Florida Panthers announced a multi-year partnership making Amerant the Official Bank of the Florida Panthers and FLA Live Arena. Terms of the agreement were not disclosed. Amerant will also become the presenter of the Panthers premium club. Lounge 954, FLA Live Arena's premium center-ice seating area, will now be known as the 'Amerant Vault.' The expanded relationship will also include curated opportunities during home games at FLA Live Arena, furthering Amerant's efforts to provide a truly unique customer experience. The partnership builds on Amerant's current sponsorship as the Panther's primary home and away game helmet partner.

09:06 EST INmune Bio's trial of Alzheimer's approved to proceed in Canada - INmune Bio announced that Health Canada has issued the company a "No Objection Letter" to proceed with the company's trial using XPro1595 to treat mild Alzheimer's Disease in Canada. The first patient in the Phase 2 trial recently completed all dosing and has enrolled in an open-label extension study in Australia.

09:04 EST Fat Brands appoints Jeremy Theisen as Chief Growth Officer - Fat Brands appointed its first Chief Growth Officer, Jeremy Theisen. Prior to joining Fat Brands, Theisen served as Chief Revenue Officer of PathSpot, a hygiene management system. Theisen also served as Chief Sales Officer of Punchh.

09:04 EST CerebrumX to use Ford connected vehicle data to support UBI-as-a-service - CerebrumX Lab, an AI-driven automotive data services & management platform, announced it will incorporate Ford connected vehicle data to support its data-driven usage-based insurance-as-a-Service model for Insurers. This model offers a quicker and more cost-effective implementation of UBI programs by using embedded telematics for eligible Ford and Lincoln connected vehicles, CerebrumX said in a statement.

09:03 EST Red Rock Resorts announces special dividend of $1.00 per Class A share - Red Rock Resorts announced that the company's Board of Directors has declared a special dividend of $1.00 per Class A common share. The special dividend will be payable on December 9, 2022 to all stockholders of record as of the close of business on November 30, 2022. Prior to the payment of such dividend, Station Holdco LLC will make a cash distribution to all unit holders of record, including the company, of $1.00 per unit for a total distribution of approximately $108.1M, approximately $62.1M of which is expected to be distributed to the company and approximately $46M of which is expected to be distributed to the other unit holders of record of Station Holdco.

08:57 EST Conduent introduces BenePath Suite of Solutions - Conduent Incorporated introduced its BenePath Suite, a set of digital solutions designed to modernize the eligibility and enrollment process for social services and government aid programs, from start to finish. The BenePath Suite delivers cloud-based, modular products that agencies can use for application processing, eligibility assistance, enrollment broker services, program education and outreach, and digital communication to beneficiaries.Conduent's BenePath Suite offers numerous operational benefits for state agencies and service enhancements to the recipients that they serve. Agencies can use the Suite to address the challenges associated with reaching constituents whose eligibility may have changed since the COVID-19 pandemic and to achieve federal, state and local regulatory compliance. "States are always looking for cost-effective ways to modernize and enhance services for programs like Medicaid so they can improve delivery of benefits to recipients while reducing costs and improving efficiency," said Scott Cade, General Manager of Eligibility and Engagement at Conduent. "Our BenePath Suite is designed to enable agencies to expedite the delivery of services, enhance customer satisfaction and provide the on-demand, self-service experiences that constituents now expect - particularly as requirements change and agencies must quickly adapt."

08:46 EST Desktop Metal announces 'multimillion-dollar' contract award from VA - Desktop Metal announced a three-year, multimillion-dollar contract with the Veterans Health Administration to develop, test, and manufacture a variety of 3D printed healthcare products with a revolutionary new FreeFoam material. FreeFoam is currently being printed exclusively on the ETEC Xtreme 8K top-down DLP printing system, with broad commercial availability slated for 2023. ETEC is Desktop Metal's industrial polymer brand. The VA will receive an Xtreme 8K, as well as a variety of other equipment, in addition to development and design support for the project. The initial contract award, for $2 million, has the potential to grow to $7 million after successful phase-gate deliveries. "Desktop Metal is proud to partner with the Veterans Health Administration on this visionary project to advance health care, logistics, and decentralized manufacturing with our new 3D printing technology at production volumes," said Ric Fulop, Founder and CEO of Desktop Metal. "Our team is passionate about using Additive Manufacturing 2.0 technology such as our ETEC Xtreme 8K and FreeFoam material to transform the way manufacturing is done to deliver all-new benefits at scale."

08:43 EST NLS Pharmaceutics successfully appeals Nasdaq delisting notice - NLS Pharmaceutics announces that on November 11 it received a letter from the Nasdaq Hearings Panel indicating the Panel's decision to grant the Company's request to continue its listing on the Nasdaq Stock Market The continued listing is subject to the conditions that: (i) on or before January 19 the Company shall provide the Panel with updated proforma financial statements for the year ended December 31 and the period ended March 31 for review; and (ii) on or before February 28 the Company will demonstrate compliance with Listing Rule 5550(b)(1), which requires that the Company maintain stockholders' equity of at least $2,500,000. In order to fully comply with the terms of this exception, the Company must be able to demonstrate compliance with all requirements for continued listing on Nasdaq. In the event the Company is unable to do so, its securities may be delisted from Nasdaq. During the Exception Period, the Company is required to provide prompt notification of any significant events that occur during this time that may affect the Company's compliance with Nasdaq requirements, including, but not limited to, any event that may call into question the Company's ability to meet the terms of the exception granted.

08:41 EST Flora Growth partners with 357 Company to launch 357 Canna Logistics - The 357 Company is launching the 357 Canna Logistics division as an expansion beyond its 357 Hemp Logistics division that specializes in shipping federally legal hemp within the U.S. 357 Canna Logistics will initially focus on logistics management and shipping of cannabis and hemp between countries that have legalized it. 357 is launching 357 Canna Logistics with its launch partner, Flora Growth and several other cannabis companies, who are currently shipping throughout the EU, UK, US, and South America, with more countries to be added by year-end.

08:39 EST VivoPower to supply Australia's Evolution Group with EV conversion services - VivoPower and its wholly-owned subsidiary, Tembo EV Australia, has entered into a Supply Agreement with the Evolution Group for the full electrification of its fleet of light utility vehicles for traffic management and fleet management. Under the definitive agreement, Tembo Australia will convert existing and new vehicles to full electric over the next 5 years, subject to the successful completion of commercial and technical on-road trials, with a target to have the first fully electrified utility vehicle certified and roadworthy in 2023.

08:36 EST SAIC awarded $757M U.S. Army contract for software management services - Science Applications International has been awarded a contract to continue providing software development and management services for the U.S. Army Enterprise Service Desk. The single-award contract has estimated ceiling value of $757M. "We are excited to help the U.S. Army develop an IT enterprise management platform that will replace its legacy systems and provide a better, modernized user experience," said Bob Genter, president, Defense & Civilian Sector at SAIC. "SAIC's proven capabilities in cloud migration, software engineering and IT managed services provide solutions that align with the Army Enterprise Service Management Framework and will enhance IT service delivery across the Army." Under this contract, SAIC will continue existing AESD operations, optimize Army Enterprise Service Management Framework AESMF service delivery processes, and expand the functionality provided by the software as a service environment via optional capabilities. SAIC will also migrate legacy IT service management systems to a modern IT Service Management platform using ServiceNow. Additionally, SAIC will provide service desk solutions to include service desk support for voice, messaging, video teleconferencing, computing, network infrastructure, customer support and information assurance support to the Army.

08:33 EST VolitionRx announces clinical research study with Oncovet - VolitionRx Limited announced a clinical research study with Oncovet, a veterinary referral clinic, specializing in medical and radiation oncology. The non-interventional study is being led by Dr. Jerome Benoit, Oncovet's Clinical Director, and will evaluate circulating nucleosomes of dogs and cats with cancer using Volition's Nu.Q Vet Cancer Test.

08:32 EST 3D Systems announces addition of two new materials to its materials portfolio - 3D Systems announced the addition of two new materials - Certified HX and Certified CuCr2.4 - to its materials portfolio. Both materials are certified for use with the company's DMP Flex 350, and DMP Factory 350 3D printers, and HX is also certified for the DMP Factory 500 to address a breadth of applications requiring high strength and corrosion-resistance in industries such as energy, industrial gas turbines, high tech, consumer goods, aerospace & defense, and automotive.

08:32 EST Freightos announces transactions, gross booking value for Q3 - As previously announced, Freightos has entered into a definitive business combination agreement with Gesher I Acquisition Corp., a special purpose acquisition company, that is expected to result in Freightos becoming publicly listed on Nasdaq. #Transactions grew dramatically to 192 thousand, up 178% year over year and 28% from the second quarter, resulting in GBV of $159 million. The number of air and ocean carriers receiving direct eBookings on the Freightos platform increased to 32. Revenue was $4.7M, up 56% y/y.

08:28 EST Minerals Technologies appoints Erik Aldag as CFO - Minerals Technologies announced that Erik Aldag, Director, Investor Relations, Financial Planning & Analysis, has been promoted to Senior VP, Finance and Treasury, and CFO, succeeding Matthew Garth, who is leaving MTI to pursue another opportunity. Aldag joined MTI in 2017 as Director, Financial Planning & Analysis and assumed the additional responsibility for Investor Relations in 2020. In his new role, Mr. Aldag will serve as an officer of the company and a member of the executive management committee.

08:26 EST Electriq Power to become public through TLG Acquisition One merger agreement - Electriq Power and TLG Acquisition One (TLGA) announced that they have entered into a definitive merger agreement. Upon closing of the transaction, which is expected during the first half of 2023, the combined company will operate under the name Electriq Power Holdings and will be led by existing Electriq management with Mike Lawrie joining the board as chairman. The transaction values Electriq at a pro forma pre-money equity value of $495M, and the combined company plans to publicly trade on the NYSE under the symbol (ELIQ). The transaction values Electriq at a pro forma pre-money equity value of $495M and is expected to provide Electriq with up to $125M of capital to fund its growth through a combination of debt and equity. Electriq is in advanced discussions for up to $60M of capital that includes an asset-backed revolving credit facility from a leading institutional investor, a personal convertible debt commitment of up to $8.5M from TLGA CEO Mike Lawrie and other convertible debt to be raised before transaction close. Electriq intends to close and partially fund the revolving credit facility and the convertible debt from Mr. Lawrie before year end 2022. In addition, a meaningful number of shares will be placed into escrow to provide incentives for equity financing commitments. TLGA may also enter into a forward purchase agreement prior to transaction close to backstop redemptions for up to $100M. The boards of directors of both Electriq and TLGA have approved the proposed transaction, which is expected to be completed during the first half of 2023, subject to, among other things, approval by TLGA's stockholders and satisfaction or waiver of the other conditions stated in the definitive documentation. Upon close of the transaction, Electriq's existing shareholders will continue to own a majority of the merged company. Additional information about the proposed transactions, including a copy of the business combination agreement, related ancillary agreements in connection with the proposed business combination, and an investor presentation, will be available in a Current Report on Form 8-K to be filed by TLGA with the Securities and Exchange Commission, which will be available on the SEC's website.

08:24 EST East Stone Acquisition and NWTN announce closing of business combination - East Stone Acquisition and NWTN, an eco-conscious mobility technology company providing passenger-centric green premium mobility solutions, announced that the business combination of East Stone and NWTN was approved by shareholders at a Special Meeting on November 10, and the transaction closed November 11. The combined company will retain the NWTN name, and its Class B ordinary shares and warrants are expected to begin trading on the Nasdaq under the symbol "NWTN" on November 14.

08:22 EST NV5 Global awarded $15M cultural resources contract in Georgia - NV5 Global has been awarded a three-year, $15M contract to provide cultural resources services to support the design and development of transportation facilities and assets for the Georgia Department of Transportation's Office of Environmental Services. NV5 will deliver engineering services related to archaeological and historical sites, including artifact curation, archaeological survey, testing, permitting, historic rehabilitation studies for structures, and National Register of Historic Places nominations.

08:21 EST Assembly Biosciences begins dosing in Phase 1a trial of ABI-4334 - Assembly Biosciences announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334. 4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA formation and new virus production versus first-generation core inhibitors. In preclinical research, 4334 has demonstrated sub-nanomolar potency against pgRNA encapsidation and 2-3 nanomolar potency against cccDNA formation. The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics of 4334 following single ascending dose and multiple ascending dose administration in healthy participants. The objectives of the study include the proportion of subjects with adverse events, premature treatment discontinuation due to AEs and abnormal laboratory results. Results of the trial will support dose selection for a future Phase 2 trial.

08:19 EST Dare Bioscience's DARE-VVA1 shows positive Phase 1/2 results in VVA - Dare Bioscience announced topline data from its Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed for the treatment of moderate to severe vulvar and vaginal atrophy. The randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of DARE-VVA1 in postmenopausal participants with moderate to severe VVA. The topline data from the study demonstrated safety and tolerability of DARE-VVA1, as well as improvement in the vaginal cytology parameters and the bothersome vaginal symptoms associated with VVA. DARE-VVA1 has the potential to be the first therapeutic specifically approved for the treatment of VVA in U.S. patients with HR+ breast cancer. There are currently no FDA-approved products labeled for VVA treatment in HR+ breast cancer patients.

08:18 EST Universe Pharmaceuticals regains compliance with Nasdaq bid price requirement - Universe Pharmaceuticals received a written notification from Nasdaq informing the company that it has regained compliance with the Nasdaq's minimum bid price requirement and the matter is closed. Nasdaq stated that accordingly, the Company has regained compliance with the Listing Rule.

08:15 EST 9 Meters announces continued immuno-oncology pact with Gustave Roussy - 9 Meters Biopharma announced a continuing collaboration agreement with Gustave Roussy, a cancer center in France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into the systemic circulation. This collaboration focuses on the relationship between intestinal microbiome composition and systemic responses to cancer treatments such as chemotherapy and immune checkpoint inhibitors ICIs. Specifically, the work tested the hypothesis that the therapeutic effect of ICIs, such as antibodies to CTLA-4 and PD-1, might be enhanced by preventing bacterial antigens, toxins, and certain metabolites in the gut from interacting with the host immune system utilizing NM-102.These studies showed that NM-102 was effective both when alone and when combined with ICIs in a transgenic mouse model of spontaneous aggressive skin melanoma. Furthermore, the combination of NM-102 with ICIs improved survival compared to ICIs alone. ngoing. The Company intends to move forward with an IND-enabling pathway with indication selection in 2023.

08:13 EST Stryve Foods appoints Whitehair to board of directors - Stryve Foods (SNAX) announced Chris Whitehair as a new addition to the Company's Board of Directors. Whitehair currently serves as Senior Vice President of Supply Chain and Operations for SunOpta (STKL). While in this role over the last several years, he has led the development and execution of optimizing their network.

08:12 EST AMC Entertainment announces fourth-highest attended weekend in 2022 - AMC Theatres welcomed an overall more than 4.9M moviegoers at its locations in the United States and internationally, with most of these guests celebrating a return to Wakanda this past weekend. This represents AMC's fourth-highest attended weekend globally in 2022. AMC's global admissions revenue during the weekend, Thursday through Sunday, was well ahead of the same weekend in 2021 by approximately 125%, and also outpaced that same weekend of 2019 by approximately 53%. AMC's performance was driven primarily by the record-setting opening of Marvel's "Black Panther: Wakanda Forever," which set a domestic box office record for films opening during the month of November with reported weekend ticket sales of $180M. It grossed some $330M globally. In the United States, AMC enjoyed its fourth busiest weekend of 2022 and fifth busiest weekend since reopening in 2020. On Saturday in the U.S., AMC recorded its highest food & beverage sales for any November day in AMC's 102-year history. AMC currently expects that Black Panther: Wakanda Forever will wind up being the second highest grossing movie for FY22.

08:10 EST Curaleaf announces strategic national rebrand of Grassroots - Curaleaf Holdings announced the national rebrand of its Grassroots premium cannabis flower brand, and shared details on the brand's previously announced expansion into California with the launch of Diamond Infused Pre-Rolls. The rebrand of Grassroots coincides with the launch of its Grower's Reserve program, an ongoing series of limited-edition collaborations with craft farmers and diverse operators in California.

08:09 EST Trinity Capital announces $25M stock repurchase program - Trinity Capital announced that its board of directors has authorized a program for the purpose of repurchasing up to $25M worth of thecompany's common stock. Unless amended or extended by Trinity's board of directors, the company expects the repurchase program to be in place until the earlier of November 11, 2023, or until $25M of Trinity's outstanding shares of common stock have been repurchased.

08:08 EST Starry receives notice of NYSE trading share price listing rule non-compliance - Starry Group Holdings announced that on November 8, it had received a deficiency letter from the New York Stock Exchange notifying the Company that it is not in compliance with applicable price criteria in the NYSE's continued listing standards because, as of November 7, the average closing price of the Starry's Class A Common Stock was less than $1.00 per share over a consecutive 30 trading-day period. Pursuant to the NYSE's rules, Starry has a six-month period following receipt of the deficiency letter to bring its share price and average share price back above $1.00. The NYSE rules require Starry to notify the NYSE within 10 business days of receipt of the NYSE notice of its intent to cure this deficiency. Starry plans to notify the NYSE of its intent to cure within the applicable time period. Starry's Class A Common Stock will continue to be listed and trade on the NYSE during this period, subject to Starry's compliance with other NYSE continued listing standards. Starry's receipt of the deficiency letter does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission.

08:07 EST Pacira reports October preliminary product sales $54.9M - Pacira reported preliminary unaudited net product sales of $54.9M for October. The company's net product sales include Exparel, Zilretta and the iovera degrees system. Exparel net product sales were $45.0M vs. $42.5M for October 2021. Zilretta net product sales were $8.6M for October 2022. Zilretta sales in October 2021 occurred prior to the completion of the company's acquisition of Flexion in November 2021. iovera net product sales were $1.3M for October 2022 vs. $1.2M for October 2021. Since early 2020, the company's revenues have been impacted by COVID-19 and pandemic-related challenges that included the significant postponement or suspension in the scheduling of elective surgical procedures due to public health guidance and government directives. While the degree of impact has diminished during the course of the pandemic due to the introduction of vaccines and the lessening of elective surgery restrictions, certain pandemic-related operational challenges persist. It remains unclear how long it will take the elective surgery market to normalize or if restrictions on elective procedures will recur due to future COVID-19 variants or otherwise.

08:07 EST Beam Global receives $2.9M order from U.S. DHS for Beam EV ARC charging systems - Beam Globa announced that the U.S. Department of Homeland Security, DHS, has ordered 32 Beam EV ARC sustainable off-grid charging systems and 3 ARC Mobility trailers for efficient system transport. The systems will be deployed across 8 locations for Customs Border Patrol, CBP, Federal Law Enforcement Training Centers, FLETC, and the Federal Emergency Management Agency, FEMA. EO 14057 Catalyzing Clean Energy Industries and Jobs Through Federal Sustainability prioritizes federal investment in energy resilient infrastructure for EV charging, powered by locally produced and delivered renewable energy for America's next generation electricity supply. The purchase was made through the General Services Administration Multiple Award Schedule. The DHS charging systems will be deployed in Georgia, Maryland, New Mexico, South Carolina, and 4 locations in Puerto Rico. "Our products are perfect for Executive Order for a Clean Energy Economy: resilient, clean, sustainable and rapidly deployed EV charging infrastructure solutions," said Desmond Wheatley, Beam Global CEO. "We continue to see increasing federal GSA orders and pipeline opportunities citing federal initiatives. Our sustainable EV charging solutions create American manufacturing jobs to build American made products that serve zero emission transportation with 100% locally generated renewable and resilient energy."

07:59 EST Hyundai Motor signs MoU with Nusantara Capital City Authority - Hyundai Motor Group has signed a Memorandum of Understandingwith the Nusantara Capital City Authority to work together to establish an advanced air mobility ecosystem in Indonesia. The MoU was conducted during the B20 summit at Bali Nusa Dua Convention Center, Indonesia. The MoU aims to introduce AAM as part of a smart mobility ecosystem in the new capital city that Indonesia is working to establish. The Group plans to develop a roadmap and review the concept of consolidated mobility for ground and air while carrying out an AAM demonstration project and test flights. "Implementing advanced air mobility in Nusantara is in line with OIKN's spirit of being a 'living laboratory' in Indonesia, open to creating a culture of new learning, working and lifestyle," said Bambang Susantono, Head of the Capital City Nusantara Authority. "We value Hyundai Motor Group's cooperation in developing Nusantara as a smart and sustainable city."

07:58 EST Medigus subsidiary filed patent with USPTO for wireless charging method - Medigu announced that its wholly owned subsidiary, Charging Robotics, filed a patent application with the United States Patent and Trademark Office, USPTO. The new patent refers to a unique wireless charging method for electric vehicles parked at automatic car parking systems and parking garages."The use of electric vehicles has increased dramatically over the last few years, and the trend is expected to continue growing. Accessible charging stations to the public have become increasingly important as electric vehicle use increases. The latest patent filed by Charging Robotics enables upgrades to current parking solutions and addresses the increasing demand from drivers to easily charge their vehicles," said Liron Carmel, CEO of Medigus. "We believe that Charging Robotics has the capability of solving pressing problems in the electric charging infrastructure sector and providing added value to owners and users of car parks."

07:57 EST Oramed signs deal with Medicox to commercialize oral insulin in South Korea - Oramed Pharmaceuticals announced it has signed an exclusive commercial distribution agreement for the Republic of Korea with Medicox Co., Ltd., an emerging biotech company. The agreement grants Medicox an exclusive license to apply for regulatory approval for and distribute Oramed's oral insulin candidate for ten years in the Republic of Korea. Medicox will purchase ORMD-0801 at an agreed upon transfer price and will additionally pay Oramed up to $18M, $2M of which have already been received by Oramed to date, in developmental milestones and up to 15% royalties on gross sales. Medicox will additionally be responsible for gaining regulatory approval in Republic of Korea.

07:53 EST Kaleyra receives NYSE non-compliance letter regarding stock trading price - Kaleyra announced that the company received a written notice from the New York Stock Exchange that it was not in compliance with the continued listing criteria set forth in Section 802.01C of the NYSE's Listed Company Manual, as the average closing price of the company's common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Company intends to respond to the NYSE within ten business days of receipt of the Notice with respect to its intent to cure the deficiency, as required by Section 802.01C. The company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to shareholder approval, if necessary, to regain compliance. Pursuant to Section 802.01C, the company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the consecutive 30 trading-day period ending on the last trading day of that month. If the company is unable to regain compliance with the $1.00 share price rule within this period, the NYSE will initiate procedures to suspend and delist the Common Stock.

07:53 EST Solaris Resources announces assay results from Warintza Project - Solaris Resource reports assay results from a series of holes aimed at delineating resources at the Warintza East discovery within its Warintza Project in southeastern Ecuador. Jorge Fierro, Vice President, Exploration, commented: "Drilling to date covers only a small portion of the Warintza East discovery, which represents a target for major resource growth. Further extensional and step-out drilling is planned to the east and southeast with a 400m step-out platform located on the southern margin of the drill grid targeting strong soil anomalism in this area."

07:52 EST Venator Materials to divest iron oxide business for $140M - The company said, "In addition to the recently announced $51 million sale-leaseback transaction, we have entered into a definitive agreement to sell our iron oxide business from within our Color Pigments business to Cathay Industries for an enterprise value of $140 million. The average EBITDA of this business in 2020 and 2021 proforma adjusted for the impact of the sale-leaseback was $16 million. We believe Cathay will be an excellent long-term strategic owner of the business going forward. The transaction is expected to close by the end of the first quarter in 2023."

07:47 EST Aptose treats first patient with dosing of continuous G3 form of luxeptinib - Aptose Biosciences announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory acute myeloid leukemia.The new G3 formulation thus far has been tested as a single dose in 20 patients from an ongoing Phase 1 clinical program of luxeptinib. Patients now will receive continuous dosing at the 50mg G3 Q12h dose, with the protocol allowing for further dose escalation of G3 in subsequent patients. "We're pleased to incorporate the new G3 formulation of luxeptinib into our clinical trial," said William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer. "Preclinically, Lux is an extraordinary molecule, eradicating tumors with the absence of toxicity, and clinically, one patient administered the original G1 formulation in the AML trial achieved exposures that enabled a complete remission (CR). We are hopeful the G3 formulation will result in greater exposures of luxeptinib and additional responses in this difficult-to-treat patient population."

07:45 EST Satsuma Pharmaceuticals announces results from SUMMIT phase 3 trial of STS101 - Satsuma Pharmaceuticals reported topline results from the STS101 SUMMIT Phase 3 efficacy trial. Although topline data showed numerical differences in favor of STS101 5.2 mg versus placebo on the pre-specified co-primary endpoints of freedom from pain and freedom from most bothersome symptom at two hours post-administration, these differences did not achieve statistical significance. STS101 did, however, demonstrate significant effects on both freedom-from-pain and MBS-free endpoints by three hours post-dose and at all subsequent timepoints at which efficacy was assessed. In addition, STS101 was statistically superior to placebo on multiple key secondary endpoints considered clinically relevant and recommended for assessment in acute-treatment-of-migraine efficacy trials by the U.S. Food and Drug Administration in its current industry guidance document and/or the International Headache Society's guidelines for controlled trials. Consistent with clinical trial experience to date, STS101 demonstrated a favorable safety and tolerability profile in SUMMIT. "We are surprised and disappointed that STS101 did not demonstrate statistically significant superiority over placebo at two-hours post treatment on the SUMMIT study co-primary endpoints," stated John Kollins, Satsuma's President and Chief Executive Officer. "However, based on our interactions to date with the FDA, we believe the results from the STS101 Phase 1 pharmacokinetic and ASCEND Phase 3 open-label, long-term safety trials will support the STS101 NDA filing and marketing approval. A large proportion of people with migraine do not achieve sufficient and sustained relief with current treatments, and we believe that in total, the data from the STS101 clinical program, in which more than 1,600 subjects treated more than 8,500 migraine attacks with more than 10,000 doses of STS101, demonstrate that STS101 has a differentiated profile and may address the unmet needs of many patients." In addition, Satsuma announced that it does not plan to invest in commercializing STS101 and will actively explore alternatives to maximize value for shareholders, while minimizing cash expenditures. As of October 31, 2022 the company had estimated cash and equivalents $59.4 million.

07:42 EST Infinity Pharma provides MARIO-3 update in TNBC patients - Infinity Pharmaceuticals reported an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple negative breast cancer TNBC patients. "Given our goal of improving long-term patient outcomes, we are particularly pleased to see that the addition of eganelisib to standard of care therapy showed benefit in the one-year progression free survival rate in MARIO-3 regardless of PD-L1 status," said Robert Ilaria, Jr., MD, Chief Medical Officer of Infinity. "These data reinforce the positive two-year landmark overall survival data from MARIO-275 in 2L urothelial cancer, also regardless of PD-L1 status, and the encouraging PFS observed in checkpoint inhibitor refractory squamous cell cancer of the head and neck in our MARIO-1 study, which all support the potential of eganelisib to improve long term outcomes for patients."

07:40 EST The Real Brokerage Inc. announces Andrew Kazeniac as COO - The Real Brokerage announced Andrew Kazeniac has been appointed COO, effective immediately. As COO, Kazeniac will be responsible for driving operational efficiencies and continuing to enhance the level of service provided to Real agents through its technology platform. Most recently, he served as Vice President of Retail Operations at Drizly.

07:34 EST Ascendis Pharma submits EMA marketing authorisation for Transcom - Ascendis Pharma has submitted a Marketing Authorisation Application to the European Medicines Agency - EMA - for TransCon PTH in adult patients with hypoparathyroidism. TransCon PTH is an investigational prodrug designed to restore parathyroid hormone to physiological levels over 24 hours in adult patients with hypoparathyroidism. Hypoparathyroidism is a rare disease that affects an estimated 85,000-223,000 patients in Europe. TransCon PTH has been generally well tolerated, with no discontinuations related to study drug. The company's New Drug Application for TransCon PTH for adult patients with hypoparathyroidism is under Priority Review by the FDA, with a PDUFA target action date of April 30, 2023. TransCon PTH has been granted orphan designation in the U.S. and European Union.

07:32 EST Apexigen announces positive Phase 2 results of sotigalimab in liposarcoma - Apexigen announced topline data from an ongoing Phase 2 trial evaluating sotigalimab, Apexigen's agonist antibody targeting CD40, in combination with standard of care doxorubicin, in patients with advanced soft tissue sarcoma. In the subgroup of patients with liposarcoma, the second most common STS, treatment with sotigalimab combined with dox resulted in a median progression-free survival of 12.45 months relative to the historically observed mPFS of less than 5 months in patients treated with dox monotherapy. The objective of this ongoing study is to evaluate the efficacy of this novel combination and to further characterize the safety and feasibility of the combination of sotigalimab with dox. Sotigalimab combined with dox led to encouraging PFS in the completed LPS cohort consisting of dedifferentiated liposarcomas. As of September 27, 2022, of the 10 evaluable patients with LPS, the mPFS was 12.45 months, which compares favorably to the historically observed mPFS of LPS patients treated with dox alone. Results support the initiation of an expansion cohort with an additional 10 patients to inform a potential phase 3 registration-enabling trial in first-line LPS patients.

07:30 EST Bruker announces deal to acquire Neurescence, terms undisclosed - Bruker Corporation announced the signing of the definitive agreement to purchase 100% of the shares of Neurescence. Neurescence's flagship product Chromatone moves illumination and detection hardware off the animal head. This enables simultaneous imaging and stimulation of three sub-types of neurons in up to four regions for flexible investigation of the central nervous system with single-neuron resolution in naturalistic behavior. This platform creates strong synergies with Bruker's existing Ultima multiphoton solutions and newly acquired Inscopix head-mounted miniscopes. Financial details of the agreement were not disclosed. "Our differentiated system provides a viable means of performing multi-region-of-interest investigation with minimal weight impact to subject animals," said Dr. Yasaman Soudagar, Co-Founder and CEO of Neurescence. "Now, with Bruker, we can greatly increase the worldwide reach of this technology to enable researchers to gain deeper knowledge of neural network functions."

07:28 EST AST SpaceMobile deploys commercial communications array in low Earth orbit - AST SpaceMobile announced that it had successfully completed deployment of the communications array for its test satellite, BlueWalker 3 BW3" in orbit. 693-square foot array on Blue Walker 3 successfully completed deployment. BW3 is the largest-ever commercial communications array deployed in low Earth orbit and is designed to communicate directly with cellular devices via 3GPP standard frequencies at 5G speeds. Now that it has been unfolded, the satellite spans 693 square feet in size, a design feature critical to support a space-based cellular broadband network. The satellite is expected to have a field of view of over 300,000 square miles on the surface of the Earth.

07:27 EST TransAlta announces public offering of senior notes - TransAlta Corporation announced it has commenced a U.S. public offering of its senior notes. TransAlta intends to use the net proceeds from the sale of the notes to repay C$100M drawn on its credit facility and replace balance sheet cash used to fund the repayment in full of TransAlta's 4.500% unsecured senior notes on November 15, 2022 and pay any related fees and expenses. TransAlta also intends to allocate an amount equal to the net proceeds from this offering to finance or refinance, in part or in full, new and/or existing eligible green projects in accordance with our Green Bond Framework. The Framework received a second-party opinion from Sustainalytics which verified that it aligned with the Green Bond Principles from the International Capital Markets Association. The precise timing, size and terms of the offering are subject to market conditions and other factors. RBC Capital Markets LLC, BofA Securities Inc. and CIBC Capital Markets LLC are joint book runners for the offering which is being made pursuant to a preliminary prospectus supplement dated November 14, 2022, to a short form base shelf prospectus of TransAlta dated June 28, 2021, which forms a part of and is included in TransAlta's registration statement on Form F-10.

07:24 EST HireRight announces $100M share repurchase program - HireRight announced its board of directors has authorized a two-year $100M share repurchase program. Under the repurchase program, the company may purchase shares of its common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions, or other means, including through Rule 10b5-1 trading plans. The timing and actual number of shares repurchased will depend on a variety of factors, including stock price, trading volume, market conditions and other general business considerations. The repurchase program may be modified, suspended, or terminated at any time. Repurchases under this program may be funded from the company's existing cash and cash equivalents and future cash flows. As of September 30, the company had $146.5M in cash and cash equivalents.

07:22 EST Kezar Life Sciences presents complete data set from MISSION trial - Kezar Life Sciences announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis, or LN, at the American College of Rheumatology, or ACR, Convergence in Philadelphia, Pennsylvania. The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN. During the 24-week treatment period, patients received 60 mg of zetomipzomib subcutaneously once weekly in addition to stable background therapy. End-of-treatment, or EOT, assessments occurred at Week 25, with completion of the study at Week 37. Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN. The primary efficacy endpoint for this trial was the proportion of patients achieving an overall renal response, or ORR, measured as a 50% or greater reduction in urine protein to creatinine ratio, or UPCR, at EOT. A key secondary efficacy endpoint was the number of patients with a complete renal response, or CRR, measured as an absolute reduction in proteinuria values to a UPCR of 0.5 or less, with preserved renal function, or eGFR, and corticosteroid use of 10 mg or less prednisone/prednisone equivalent and no use of prohibited medication. Exploratory endpoints included measures of systemic lupus erythematosus, or SLE, disease activity, including Systemic Lupus Erythematosus Disease Activity Index 2000, or SLEDAI-2K, Cutaneous Lupus Erythematosus Severity Index-Activity, or CLASI-A, Physician Global Assessment and Patient Global Assessment scores. In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37. Zetomipzomib treatment demonstrated steady and clinically meaningful renal responses with additional ORRs and CRRs observed during the safety follow-up period. 10 out 17 patients achieved an ORR as early as Week 13. At EOT, 11 of 17 patients achieved an ORR, measured as a 50% or greater reduction in UPCR compared to baseline, the primary endpoint of the clinical trial. During the safety follow-up period, clinical responses deepened, and ORRs increased to 16 of 17 patients at Week 29 and 15 of 17 patients at EOS. In addition, UPCR was reduced to clinically meaningful levels: 11 of 17 patients achieved a UPCR of 0.5 or less at EOS. 15 of 17 patients (88.2%) achieved a UPCR of 0.7 or less at EOS. Median UPCR was 0.32 at EOS. 5 out 17 patients achieved a CRR as early as Week 13. At EOT, 6 of 17 patients achieved a CRR, a key secondary efficacy endpoint, measured as a UPCR of 0.5 or less, stable eGFR, daily prednisone/prednisone equivalent dose of 10 mg or less, and no use of prohibited medication. During the safety follow-up period, an additional patient achieved a CRR, with the total CRRs increasing to 7 of 17 patients at Week 29 and EOS, demonstrating a deepening renal response throughout the 37-week trial. Urinary CD163, a biomarker that is associated with active inflammation in the kidney, decreased and showed a strong correlation to UPCR across all timepoints in the study. These data suggest that patients had active inflammation at baseline despite standard-of-care therapy and that the addition of zetomipzomib reduced inflammation. By Week 13, 14 of 17 patients achieved a daily corticosteroid dose of 10 mg or less, despite no protocol-mandated steroid taper. Doses of background immunosuppressive agents remained stable throughout the study, including during the 12-week safety follow-up. Key measurements of SLE disease activity were reduced. There was no evidence of early rebound of inflammation following discontinuation of zetomipzomib. SLEDAI-2K, a global assessment of SLE disease activity, reduced from a mean of 11.3 at baseline to 6.5 at EOT and 5.8 at EOS. CLASI-A, a measure of active SLE skin disease, was elevated in 11 patients at baseline, and was reduced from a mean of 5.7 at baseline to 2.6 at EOT and 3.0 at EOS. Physician Global Assessment scores reduced from a mean of 57.2 at baseline to 23.9 at EOT and 16.2 at EOS. Patient Global Assessment scores reduced from a mean of 23.6 at baseline to 10.7 at EOT and 6.6 at EOS. Biomarkers of SLE activity improved or normalized in patients with abnormal baseline levels. Of the 12 patients with abnormal levels of double-stranded DNA antibody levels at baseline, 10 patients showed improved or normalized levels of anti-dsDNA at EOT, and improvement was maintained in 9 patients at EOS. 4 of 5 patients with abnormally low C3 complement at baseline demonstrated improvement at EOT. 3 of 4 patients with abnormally low C4 complement at baseline demonstrated improvement at EOT. Zetomipzomib continued to be well-tolerated over the course of the 37-week trial, demonstrating a favorable safety and tolerability profile with no new safety signals during the follow-up period. Overall, adverse events were generally mild-to-moderate and were consistent with what was previously reported with topline data from the MISSION Phase 2 clinical trial. Early terminations occurred in 4 out of 21 patients. No opportunistic or Grade 3 infections were reported in the trial.

07:16 EST Taylor Morrison unveils new build-to-rent brand, Yardly - Taylor Morrison unveiled a new brand name, Yardly. "Specializing in cottage-style, for-rent homes with private backyard space, these communities inspire residents to Live boundlessly," Taylor Morrison said in a statement. Taylor Morrison is fully committed to the continuation of its build-to-rent business under its new brand name, Yardly, following the conclusion of its licensing agreement with Christopher Todd Communities. All future Taylor Morrison build-to-rent community openings will be branded under the Yardly name.

07:14 EST RedHill accelerates opaganib's nuclear radiation protection program - RedHill Biopharma announced acceleration of opaganib's development program for protection against radiation injury and cancer radiotherapy. A recent publication in the International Journal of Molecular Sciences, entitled "Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy", describes the collective results of eight U.S. government-funded in vivo studies by RedHill and Apogee Biotechnology Corporation, as well as additional experiments, establishing opaganib's potential nuclear radiation protection capabilities. The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings. In the relevant study models, opaganib was associated with protection of normal tissue, including gastrointestinal, from radiation damage due to ionizing radiation exposure or cancer radiotherapy, as well as improvement of antitumor activity, response to chemoradiation, and enhancement of tolerability and survival. Additional independent studies demonstrate the radioprotective capacity of opaganib in bone marrow, with opaganib showing enhanced survival in mice which were irradiated with both lethal and half-lethal whole-body radiation. "Subject to further alignment with FDA, we intend to follow the Animal Rule path to approval for opaganib, based on prior FDA guidance specific to opaganib for the intended indication. Development for medical countermeasures may follow the Animal Rule, with pivotal animal model studies of efficacy applicable when human clinical trials are not ethical or feasible. In addition, we intend to seek an expedited development timeframe and eligibility for a Medical Counter Measure Priority Review Voucher. Amid the growing awareness of the need for material threat medical countermeasures and the positive observations seen in these in vivo gastrointestinal focused radiation toxicity and cancer radiotherapy studies, along with external data indicating potential radioprotective capacity of opaganib in bone marrow, we have accelerated our development plans to further test opaganib as a protective agent against nuclear radiation toxicity. We have recently initiated a new study to assess protective effects of opaganib on radiation-induced hematologic and renal toxicity, with our partner Apogee. Another meeting with the FDA is scheduled to seek further guidance on the path to homeland security medical countermeasure approval. Discussions with multiple government agencies in the U.S. and internationally, regarding funding and other governmental support, have been initiated," said Gilead Raday, Chief Operating Officer and Head of R&D at RedHill.

07:12 EST CytoSorbents announces STAR-T trial reaches 40 patients enrolled - CytoSorbents Corporation announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal - Ticagrelor trial, achieving the first enrollment milestone and triggering a pre-specified Data and Safety Monitoring Board review. This pivotal study intends to support both U.S. FDA and Health Canada marketing approval of DrugSorb-ATR in the United States and Canada, respectively, to remove the anti-thrombotic agent, ticagrelor, during cardiothoracic surgery. Dr. Michael J. Mack, Director of the Cardiovascular Service line at Baylor Scott & White Health System, Chairman of the Baylor Plano Research Center in Texas and co-Principal Investigator of the STAR-T trial commented: "Reaching our first trial enrollment milestone of 40 patients is a critical first step in the execution of the landmark STAR-T trial. Currently, cardiac surgeons are either forced to delay life-saving heart surgery in patients who are on antithrombotic drugs or proceed to operation when they are at very high risk for bleeding. The DrugSorb-ATR device is a novel approach that could potentially allow these high-risk surgeries to proceed in a safe and timely manner. We have designed two rigorous, pivotal trials to test the efficacy and safety of this novel device that if successful could make it available to all U.S. cardiac surgeons, so they can join their international colleagues who have it available and use it routinely in their everyday practice. We are currently focused on bringing the STAR-T trial across the finish line, so we can then turn our attention to STAR-D."

07:03 EST Compugen sees cash, equivalents funding operations through end of 2024 - As of September 30, 2022, cash, cash equivalents, short-term bank deposits and restricted cash totaled approximately $88 million, compared with approximately $118 million as of December 31, 2021. The Company expects its existing cash and cash related balances to fund its operating plans at least through the end of 2024. Compugen does not have any debt.

06:52 EST Sierra Metals confirms receipt of further correspondence from Kolpa, ARC - Sierra Metals confirms that it has received further correspondence from Compania Minera Kolpa, Kolpa, and Arias Resource Capital Management, ARC, regarding their previously announced unsolicited, non-binding letter of intent. The Company has been pursuing both short-term financing opportunities and the strategic review process announced in Sierra's press release dated October 18, 2022. As previously announced, CIBC Capital Markets has been engaged as financial advisor to review strategic options. Kolpa, ARC and other parties that have already expressed interest, among others, will be invited to participate and submit proposals so that they can be considered in the context of the strategic review process.

06:47 EST KalVista presents data on HAE at ACAAI 2022 meeting - KalVista Pharmaceuticals presented two posters at the 2022 meeting of the American College of Allergy, Asthma & Immunology, AACI, in Louisville, Kentucky. The first highlighted new data that reveals the significant impact of HAE attacks on the mental health, daily activities, and quality of life for people living with hereditary angioedema, HAE, receiving either parenterally delivered on-demand only treatment or prophylaxis with on-demand treatment for breakthrough attacks. More than half of people with HAE felt unable to participate in important events or activities, while nearly half felt 'less than 100% themselves' due to HAE. The second presentation focused on injection- or infusion-related adverse drug reactions, ADRs, reported in the FDA's Adverse Event Reporting System, FAERS, for currently approved on-demand hereditary angioedema, HAE, therapies. The five most frequently reported ADRs were injection site pain, site swelling, site erythema, access site complications/malfunctions, and incorrect route of product administration. "Both HAE patient feedback and FAERS data suggest that there is still a significant unmet need for on-demand treatments that have greater ease and less traumatic routes of administration," said Andrew Crockett, Chief Executive Officer of KalVista. "This is exactly why we are developing our pipeline of oral therapies, to improve the treatment experience and ultimately the lives of people living with HAE."

06:42 EST Protalix, Chiesi Global Rare Diseases resubmits PRX-102 BLA to FDA - Protalix and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver therapies and solutions for people affected by rare diseases, announced the resubmission on November 9 of a biologics license application, or BLA, to the FDA, for PRX-102 for the treatment of adult patients with Fabry disease. Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked a galactosidase-A investigational product candidate. The BLA resubmission includes a set of clinical and manufacturing data. The data were compiled from studies that involved more than 140 Fabry disease patients with up to five years of follow up including all three completed studies in the PRX-102 Phase III clinical program including the BALANCE study, the BRIDGE study and the BRIGHT study, as well as the phase I/II clinical trial of PRX-102. The phase I/II data includes data compiled from the related extension study succeeding the phase I/II study. The BLA resubmission also includes safety data compiled from the ongoing phase III extension studies of PRX-102. If approved, Protalix will be eligible to receive a milestone payment from Chiesi upon BLA approval. Protalix and Chiesi anticipate that the FDA will complete its review of the resubmission within six months of receipt.

06:34 EST GSK says GSK3036656 demonstrated early bactericidal activity in Phase IIa study - GSK plc announced "positive" results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis. "These results demonstrate the potential for GSK3036656 to be a component of simpler treatment regimens in the future which could help address the TB epidemic," the company stated. A selection of these data was presented in an oral late breaker session at the Union World Conference on Lung Health on November 11. David Barros-Aguirre, Head of Global Health Medicines R&D, GSK, said: "Existing treatments for TB can be complicated, of long duration and have serious side effects which significantly impact the lives of patients with TB around the world. Today's encouraging data provide a good foundation from which to investigate GSK3036656 in different combinations in Phase IIb/c studies, with the aim of contributing to shorter, simpler and better tolerated treatment regimens for patients with TB."

06:31 EST BitNile expects no direct impact related to crytpo exchange FTX bankruptcy - BitNile announced that it expects to have no exposure directly or through any of its subsidiaries or business units related to the collapsed cryptocurrency exchange FTX Trading Limited. Moreover, the Company states that its Bitcoin holdings are secured in custodial wallets that the Company believes mitigates the risk of loss similar to those from the FTX disruption. Milton "Todd" Ault, III, the Company's Executive Chairman, stated, "Other than the very difficult market conditions for Bitcoin in recent days, BitNile and its subsidiaries have not been disrupted by recent bankruptcies of industry participants. BitNile plans to continue to operate its Bitcoin mining operations and strive to fulfill its goals as previously outlined."

06:24 EST Embraer now sees FY22 free cash flow at least $150M - Embraer, in compliance with Resolution no. 44, issued on August 23, 2021 by the Securities Commission of Brazil, informed its shareholders and the market in general its updated projections for free cash flow for the year of 2022. In the first nine months of 2022, Embraer recorded an accumulated free cash flow higher than the company's initial expectations for the performance of the indicator in this period, mainly as a result of the improvement in operating margins, better management of working capital, tax efficiency, among other factors. In addition, Embraer highlights that, as usual, it will have a higher concentration of deliveries and revenues in the fourth quarter when compared to the seasonality of the other quarters of the year. As a result, Embraer is updating its projections for free cash flow for 2022, from $50M or more to a projection of $150 million or more for the year. All other components of the company's projections and financial information remain unchanged.

06:10 EST Ionis Pharmaceuticals, Metagenomi enter gene editing collaboration - Ionis Pharmaceuticals and Metagenomi announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients. The companies will jointly conduct research aimed initially at delivering investigational medicines for up to four genetic targets. Ionis has the right to add four more targets upon achievement of pre-determined development milestones. Under the terms of the agreement, Ionis will pay $80M upfront to Metagenomi plus the potential for future milestone payments and royalties. Wells Fargo Securities acted as financial advisor to Ionis on the transaction.

06:07 EST United Rentals to acquire Ahern Rentals for $2B - United Rentals announced that the company has entered into a definitive agreement to acquire the assets of family-owned Ahern Rentals for approximately $2B in cash. The board of directors of United Rentals unanimously approved the agreement. The transaction is expected to close prior to year-end 2022, subject to customary conditions. The purchase price of approximately $2B represents a multiple of 6.5x adjusted EBITDA for the trailing 12 months ended September 30, 2022, or 4.5x adjusted EBITDA net of cost synergies and the net present value of tax attributes estimated at $426 million. The acquisition is expected to be accretive to United Rentals' adjusted earnings per share and free cash flow generation in its first year post-close. Return on invested capital is expected to exceed the cost of capital within 24 months of closing on a run-rate basis, with an attractive IRR and NPV. United Rentals expects to realize approximately $60 million of annual revenue synergies by year three, led by the cross-selling of its specialty rental offerings to an expanded customer base. The company currently plans to pause its $1.25 billion share repurchase program through the initial phase of the integration, consistent with its approach during the integrations of similarly sized general rental transactions. Matthew Flannery, chief executive officer of United Rentals, said, "Our acquisition of Ahern Rentals supports our strategy to deploy capital to grow the core business and drive shareholder value. We view ourselves as the ideal owner of these assets within our network, as customers will benefit from the combination of the two organizations moving forward together. We're leveraging our competencies in larger-scale M&A to augment both our near- and long-term earnings power."

06:04 EST BioNTech to acquire GMP-certified manufacturing facility in Singapore - BioNTech announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech's expansion strategy to strengthen its global footprint in Asia. Supported by the Singapore Economic Development Board, the facility will serve as BioNTech's Regional Headquarters and become its first mRNA manufacturing facility in Singapore. BioNTech's Singapore mRNA manufacturing facility will create regional manufacturing capacities in support of BioNTech's growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both commercial and clinical scale, with the potential to expand the production to other drug classes, such as cell therapies. The facility will be initially equipped to manufacture a range of mRNA-based product candidates as well as authorized vaccines and therapeutics for infectious diseases. This may include the company's COVID-19 vaccine, as well as oncology product candidates if successfully developed and approved or authorized by regulatory authorities. The site will be a fully integrated mRNA manufacturing facility bringing mRNA production capabilities across drug substance and drug product, with an expected annual production capacity of up to several hundred million doses of mRNA-based vaccines after a full built-out. It is expected to create more than 100 jobs in Singapore by 2024 across multiple functions, including operations, engineering, quality, finance, human resources, as well as supply chain management, with recruiting starting immediately for first positions. The plant will be part of BioNTech's affiliate BioNTech Pharmaceuticals Asia Pacific and be fully integrated into the company's global manufacturing network.

05:52 EST Genentech announces GRADUATE I, II studies miss primary endpoints - Genentech, a member of the Roche, announced results from the Phase III GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment, or MCI, due to Alzheimer's and mild Alzheimer's dementia, collectively called early Alzheimer's disease. The studies did not meet their primary endpoints of slowing clinical decline. Gantenerumab was well tolerated including the subcutaneous administration. Study participants treated with gantenerumab showed a slowing of clinical decline in GRADUATE I and GRADUATE II of -0.31 and -0.19, respectively, from baseline score on the Clinical Dementia Rating-Sum of Boxes; however, neither was statistically significant. This represents a relative reduction in clinical decline of 8% in GRADUATE I and 6% in GRADUATE II compared with placebo. The CDR-SB measures cognitive and functional change across six areas including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's, was lower than expected with gantenerumab treatment. Genentech will present topline findings from the GRADUATE I and II studies at the upcoming Clinical Trials on Alzheimer's Disease, or CTAD, Conference on Wednesday, November 30. Amyloid-related imaging abnormalities are a common radiological finding associated with amyloid-targeting therapies. The incidence of ARIA-E in the pooled gantenerumab arms was 25%, with the vast majority being asymptomatic and very few leading to treatment discontinuation. The incidence of isolated ARIA-H was balanced across the gantenerumab and placebo arms.Genentech remains committed to Alzheimer's, one of the most complex neurological disorders and a major public health challenge. The company is continuing to develop and deliver tests to enable early and accurate Alzheimer's diagnosis and has a pipeline of investigational medicines for different targets, types and stages of the disease.

05:46 EST Caledonia Mining commences solar plant operations at Blanket Mine - Caledonia Mining announced that the new solar plant at Blanket Mine will start to generate power.

05:40 EST Jabil opens new design center in Poland - Jabil has officially opened a new design center in Wroclaw, Poland, that will develop technologies for multiple industries including the automotive and healthcare sectors. The opening of the 10,000 square foot center will provide a number of engineering jobs and extends Jabil's design capabilities in concept feasibility, development engineering, industrialization, material technology and advanced manufacturing technology. Jabil's design center in Wroclaw has a range of capabilities that include electronic power design, industrialization support, mechanical design, printed circuit board design, project management and value add/value engineering. Along with the center, Jabil will also co-locate its European Human Resources Employee Services team in Wroclaw. The HRES team will support 21 of Jabil's sites across Europe with HR tasks, working across 10 European countries and eight languages.

05:34 EST Roche says Phase 3 Alzheimer's studies failed to meet primary endpoint - Roche (RHHBY) announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment due to Alzheimer's and mild Alzheimer's dementia, collectively called early Alzheimer's disease. The studies did not meet their primary endpoint of slowing clinical decline. Gantenerumab was well tolerated, including the subcutaneous administration. Study participants treated with gantenerumab showed a slowing of clinical decline in GRADUATE I and GRADUATE II of -0.31 and -0.19, respectively, from baseline score on the Clinical Dementia Rating-Sum of Boxes, however, neither was statistically significant. This represents a relative reduction in clinical decline of 8% in GRADUATE I and 6% in GRADUATE II compared with placebo. The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected, Roche added. It said, "Roche remains committed to Alzheimer's disease, one of the most complex neurological disorders and a major public health challenge. The company is continuing to develop and deliver tests to enable early and accurate Alzheimer's diagnosis and has a pipeline of investigational medicines for different targets, types and stages of the disease." Roche was partnering with MorphoSys (MOR) on the GRADUATE I and II studies. Reference Link

05:29 EST Amazon announces 48-hour Black Friday event - Amazon announced that millions of deals at a variety of price points worldwide will be available during its 48-hour Black Friday event starting on Thursday, November 24. Customers will be able to save on must-have items across categories, including toys, electronics, fashion, beauty, and Amazon devices, and find unbelievable prices on select products from popular brands like Moroccanoil, Peter Thomas Roth, and Drybar hair care products, De'Longhi Espresso Machines, and everyday essentials from Mrs. Meyer's Clean Day.

05:20 EST First Light Acquisition Group to transfer listing to the NYSE American - First Light Acquisition Group announced that it will transfer its listing to the NYSE American, where it has been approved to list. In connection with the transfer, FLAG will voluntarily delist from The New York Stock Exchange. FLAG's decision to transfer to the NYSE American was motivated by more favorable thresholds for continued listing on the NYSE American following recent redemptions of FLAG's Class A common stock. Following the transfer, FLAG intends to continue to file the same types of periodic reports and other information it currently files with the Securities and Exchange Commission. FLAG anticipates the transfer to the NYSE American to occur on or about November 14.

05:09 EST Powerbridge acquires 19% stake of DTI Group, terms undisclosed - Powerbridge announced that the company has acquired 19% stake of DTI Group, a technology company specializing in international trade digitalization and platforms. DTI is a platform developer and service providers for Digital Trading Infrastructure & Online Dispute Resolution, a project initiated by the United Nations Conference on Trade and Development. With the strategic acquisition, Powerbridge and DTI will be working closely together to implement the United Nation's project. The objective of the project is to enhance digital trade connectivity and operations among online cross-border trade platforms and offline trade hubs in order to empower both the established and new global trade players. The project will also be equipped with various digital trade systems that encourage cooperation and communications among local and global players, which is designed to increase the overall efficiency of cross-border trade and e-commerce.